Unity Biotechnology Inc (NASDAQ: UBX) is -84.49% lower on its value in year-to-date trading and has touched a low of $0.24 and a high of $3.10 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The UBX stock was last observed hovering at around $0.3 in the last trading session, with the day’s loss setting it -0.1%.
Currently trading at $0.2, the stock is -69.07% and -73.80% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.54 million and changing -33.41% at the moment leaves the stock -84.33% off its SMA200. UBX registered -79.51% loss for a year compared to 6-month loss of -82.45%. The firm has a 50-day simple moving average (SMA 50) of $0.7638 and a 200-day simple moving average (SMA200) of $1.277085.
The stock witnessed a -70.92% gain in the last 1 month and extending the period to 3 months gives it a -77.77%, and is -47.90% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 38.35% over the week and 21.95% over the month.
Unity Biotechnology Inc (UBX) has around 16 employees, a market worth around $3.44M and $0.00M in sales. Distance from 52-week low is -16.97% and -93.55% from its 52-week high. The company has generated returns on investments over the last 12 months (-148.88%).
The EPS is expected to grow by 42.86% this year.
Unity Biotechnology Inc (UBX) Top Institutional Holders
44.0 institutions hold shares in Unity Biotechnology Inc (UBX), with institutional investors hold 17.52% of the company’s shares. The shares outstanding are 17.21M, and float is at 15.68M with Short Float at 3.65%. Institutions hold 17.19% of the Float.
Unity Biotechnology Inc (UBX) Insider Activity
The most recent transaction is an insider sale by Nguyen Alexander Hieu,the company’sCLO and Head of Ops. SEC filings show that Nguyen Alexander Hieu sold 17,852 shares of the company’s common stock on Apr 02 ’25 at a price of $1.03 per share for a total of $18388.0. Following the sale, the insider now owns 48753.0 shares.
Still, SEC filings show that on Apr 02 ’25, Sullivan Lynne Marie (CFO & Head of Corp. Dev.) disposed off 21,867 shares at an average price of $1.03 for $22523.0. The insider now directly holds 98,905 shares of Unity Biotechnology Inc (UBX).
